Industry News
Biotechnology Industry News
Two affiliates of Apple Tree…
Two affiliates of Apple Tree Partners have filed for bankruptcy, a move designed to continue funding the venture firm's portfolio biotechs as a funding dispute with a top investor plays out.
Rival European pharma giants…
Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. Paris-based Sanofi is investing in a U.S. biotech’s autoimmune research, while GSK has tapped a fellow British outfit
Formation Bio is inking a deal…
Formation Bio is inking a deal worth more than $600 million in biobucks for ex-China rights to a next-gen immunology asset from Lynk Pharmaceuticals.
Roche has lifted the lid on the…
Roche has lifted the lid on the data behind its second phase 3 giredestrant win, linking the oral selective estrogen receptor degrader to a 30% reduction in the risk of invasive disease recurrence or death.
A Chinese biotech helmed by an…
A Chinese biotech helmed by an AstraZeneca veteran has secured $108 million in series B funds, which the company will use to advance its lead KRAS inhibitor into phase 3 studies.
Emerging ADC development…
Emerging ADC development approaches such as bispecific antibodies and dual-payloads are opening new avenues to address heterogeneity and resistance. The next generation of ADCs involve a balance of innovative targets, linkers, conjugation methods, payload MOA,
CMS spending on skin substitutes…
CMS spending on skin substitutes is rising. New policies are an important first step in reform to ensure patient access and incentivize innovation.
People come to Orlando to escape….
People come to Orlando to escape. With Disney World, SeaWorld and Universal Studios all in the area, there are endless opportunities to leave behind the challenges of the real world for a bit of relaxation
Exicure’s investigational small…
Exicure’s investigational small molecule succeeded in mobilizing key blood-forming cells in almost 90% of patients in a phase 2 multiple myeloma trial, paving the way for smoother and more effective autologous stem cell transplants.
Ose Immunotherapeutics is…
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and its ulcerative colitis therapy lusvertikimab.
Pfizer’s recent bidding war for…
Pfizer’s recent bidding war for an obesity biotech clearly hasn’t satiated the pharma’s appetite for new GLP-1 therapies—at least going by this morning’s $1.9 billion biobucks deal.
The FDA is raising the bar for…
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to show
Novartis has tapped an AI-enabled…
Novartis has tapped an AI-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions.
GSK is walking away from Ideaya…
GSK is walking away from Ideaya Biosciences after a five-year-long partnership that initially focused on three of Ideaya's synthetic lethality programs.
Patients with polycythemia vera, a…
Patients with polycythemia vera, a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. But the tide may finally be turning in their favor, as Merck
The drug “has the potential to…
The drug “has the potential to transform the care of those living with DMD amenable to exon 51 skipping,” Dyne CEO John Cox said in a statement.
Dr. Reddy’s Laboratories is…
Dr. Reddy’s Laboratories is paying $20 million upfront for the rights to Immutep’s phase 3-stage LAG-3 candidate in certain territories while leaving the Australian biotech with ownership in key markets.
With the best-selling medication…
With the best-selling medication in the world in tirzepitide and a record-setting $1 trillion valuation to go with it, Eli Lilly is hardly hurting for cash. But money is only as good as what you
Amid an outpouring obesity data…
Amid an outpouring obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as both companies saw their respective
Mirum Pharmaceuticals is paying…
Mirum Pharmaceuticals is paying $620 million in cash and stock to buy Bluejay Therapeutics and its phase 3-stage hepatitis drug.